Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for InjectionAugust 12, 2025 5:30 PM EDT | Source: Medexus Pharmaceuticals Inc.Fiscal Q1 2026 net revenue of $$24.6 million, net income of $$0.5 million, operating income of $$0.9 million, and Adjusted EBITDA* of $$3.4 million$$3.0 million of product-level net revenue from GRAFAPEX in fiscal Q1 2026, relative to $$3.0 million of personnel and infrastructure investments, further supporting Med ...